Loading organizations...
§ Private Profile · Wilmington, DE, USA
clinical-stage oncology company developing targeted cancer therapies for rare cancers, focused on Notch inhibitors.
Ayala Pharmaceuticals is a clinical-stage oncology company developing targeted gamma secretase inhibitors for rare and aggressive cancers, based in Rehovot, Israel, and Monmouth Junction, New Jersey. The micro-cap biopharmaceutical firm historically operates with a team of under 50 employees to advance its lead clinical candidates, AL101 and AL102, through Phase 2 and Phase 3 trials. Prior to its public market debut, the enterprise secured roughly $70 million in private financing, followed by a $55 million IPO on the Nasdaq in 2020. The development pipeline is supported by strategic licensing agreements and investments involving prominent industry entities such as Novartis, Bristol-Myers Squibb, and aMoon Fund. To further expand its oncology portfolio, the business completed a merger with Advaxis in 2023 and subsequently agreed to merge with Biosight. Ayala Pharmaceuticals was originally founded in 2017 by Roni Mamluk.
Ayala Pharmaceuticals has raised $30.0M across 1 funding round.
Ayala Pharmaceuticals has raised $30.0M in total across 1 funding round.
Ayala Pharmaceuticals has raised $30.0M in total across 1 funding round.
Ayala Pharmaceuticals's investors include Novartis, Harel Insurance Investments & Financial Services, Israel Biotech Fund, SBI JI Innovation Fund.
Ayala Pharmaceuticals has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 28, 2019 | $30M Series B | Novartis | Harel Insurance Investments & Financial Services, Israel Biotech Fund, SBI JI Innovation Fund | Announced |